The contribution of immunology to the rational design of novel antibacterial vaccines

Nature Reviews Microbiology

Volumn 5, Issue 7, 2007, Pages 491-504

  Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE;

BACTERIAL INFECTION; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; INFECTION PREVENTION; MEMORY CELL; MEMORY T LYMPHOCYTE; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

AGED; ALLERGY AND IMMUNOLOGY; ANIMALS; B-LYMPHOCYTES; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CHILD, PRESCHOOL; DRUG DESIGN; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNOLOGIC MEMORY; INFANT; INFANT, NEWBORN; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

BACTERIA (MICROORGANISMS);

EID: 34250347630     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1688     Document Type: Review

References (143)

1. Behring, E. Die Blut Serum Therapie zur Diphterie Behandlung des Menschen. Berliner klin. Wochenschr. 31, 827 (1894).
2. WHO. World Health Report 2006: Working together for health. WHO, Geneva (2006).
3. Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med. 339, 520-532 (1998).
4. Wright, G. D. The antibiotic resistome: The nexus of chemical and genetic diversity. Nature Rev. Microbiol. 5, 175-186 (2007).
5. Peacock, S. J. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 771-832 (Hodder Arnold, London, 2005).
6. Teixeira, L. M. & Facklam, R. R. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 882-902 (Hodder Arnold, London, 2005).
7. Robinson, D. A. et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 365, 1256-1258 (2005).
8. Palleroni, N. J. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 1591-1606 (Hodder Arnold, London, 2005).
9. Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: Causes, challenges and responses. Nature Med. 10, S122-S129 (2004).
10. Murray, P. R., Holmes, B. & Auken, H. M. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 1474-1506 (Hodder Arnold, London, 2005).
11. Mims, C. et al. in Medical Microbiology 556-566 (Elsevier Mosby, Edinburgh, 2004).
12. Odeh, R. & Quinn, J. P. Problem pulmonary pathogens: Pseudomonas aeruginosa. Semin. Respir. Crit. Care Med. 21, 331-339 (2000).
13. Rappuoli, R., Miller, H. I. & Falkow, S. The intangible value of vaccination. Science 297, 937-939 (2002).
14. Manz, R. A., Hauser, A. E., Hiepe, F. & Radbruch, A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367-386 (2005).
15. Casadevall, A. & Pirofski, L. A A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. 91, 1-44 (2006).
16. Verez-Bencomo, V. et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305, 522-525 (2004).
17. Posfay-Barbe, K. M. & Wald, E. R. Pneumococcal vaccines: Do they prevent infection and how? Curr. Opin. Infect. Dis. 17, 177-184 (2004).
18. Girard, M. P., Preziosi, M. P., Aguado, M. T. & Kieny, M. P. A review of vaccine research and development: Meningococcal disease. Vaccine 24, 4692-4700 (2006).
19. Mowat, A. M. & Garside, P. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 389-402 (Hodder Arnold/ASM Press, London/Washington D.C., 2005).
20. Salerno-Goncalves, R. & Sztein, M. B. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol. 14, 536-542 (2006).
21. Zanetti, M. & Franchini, G. T cell memory and protective immunity by vaccination: Is more better? Trends Immunol. 27, 511-517 (2006).
22. Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 124, 849-863 (2006).
23. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60 (1996).
24. Kalia, V., Sarkar, S., Gourley, T. S., Rouse, B. T. & Ahmed, R. Differentiation of memory B and T cells. Curr. Opin. Immunol. 18, 255-264 (2006).
25. Jiang, H. & Chess, L. Regulation of immune responses by T cells. N. Engl. J. Med. 354, 1166-1176 (2006).
26. Belkaid, Y. & Rouse, B. T. Natural regulatory T cells in infectious disease. Nature Immunol. 6, 353-360 (2005).
27. Mora, J. R. & von Andrian, U. H. T-cell homing specificity and plasticity: New concepts and future challenges. Trends Immunol. 27, 235-243 (2006).
28. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: The promise and the challenge. Nature Rev. Immunol. 6, 148-158 (2006).
29. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
30. Inohara, N., Chamaillard, M., McDonald, C. & Nunez, G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355-383 (2005).
31. Chamaillard, M., Girardin, S. E., Viala, J. & Philpott, D. J. Nods, Nalps and Naip: Intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5, 581-592 (2003).
32. Meylan, E., Tschopp, J. & Karin, M. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
33. Colonna, M., Pulendran, B. & Iwasaki, A. Dendritic cells at the host-pathogen interface. Nature Immunol. 7, 117-120 (2006).
34. Jackson, D. C. et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 101, 15440-15445 (2004).
35. Unanue, E. R. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 375-388 (Hodder Arnold/ASM Press, London/Washington, D.C., 2005).
36. Yewdell, J. W. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 403-418 (Hodder Arnold/ASM Press, London/Washington D.C., 2005).
37. Kaufmann, S. H. E. in Fundamental Immunology, 5th edn (ed. Paul, W. E.) 1229-1261 (Lippincott-Raven, Philadelphia, New York, 2003).
38. Hayday, A. & Steele, C. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 435-448 (Hodder Arnold/ASM Press, London/Washington D.C., 2005).
39. Bonneville, M. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 449-470 (Hodder Arnold/ASM Press, London/Washington, D.C., 2005).
40. Romagnani, S. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 273-299 (Hodder Arnold/ASM Press, London/Washington, D.C., 2005).
41. Hsu, S.-C. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 419-434 (Hodder Arnold/ASM Press, London/Washington, D.C., 2005).
42. Winau, F., Hegasy, G., Kaufmann, S. H. E. & Schaible, U. E. No life without death - apoptosis as prerequisite for T cell activation. Apoptosis 10, 707-715 (2005).
43. Winau, F. et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24, 105-117 (2006).
44. Yrlid, U. & Wick, M. J. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J. Exp. Med. 191, 613-624 (2000).
45. Schaible, U. E. et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nature Med. 9, 1039-1046 (2003).
46. H2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
47. H17 cells. Nature Immunol. 7, 899-901 (2006).
48. Tato, C. M., Laurence, A. & O'Shea, J. J. Helper T cell differentiation enters a new era: le roi est mort; vive le roi! J. Exp. Med. 203, 809-812 (2006).
49. Dong, C. Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nature Rev. Immunol. 6, 329-333 (2006).
50. h17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity. 24, 677-688 (2006).
51. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 648-651 (2007).
52. Happel, K. I. et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202, 761-769 (2005).
53. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature Immunol. 8 369-377 (2007).
54. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002).
55. Ndejembi, M. P., Tang, A. L. & Farber, D. L. Reshaping the past: strategies for modulating T-cell memory immune responses. Clin. Immunol. 122, 1-12 (2007).
56. Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005).
57. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
58. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nature Immunol. 7 937-945 (2006).
59. Batten, M. et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nature Immunol. 7, 929-936 (2006).
60. + T cells and antiviral immunity. Immunity 20, 47-58 (2004).
61. Murray, P. J., Aldovini, A. & Young, R. A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl Acad. Sci. USA 93 934-939 (1996).
62. Shi, Y., Zheng, W. & Rock, K. L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 97, 14590-14595 (2000).
63. Bouwer, H. G., Alberti-Segui, C., Montfort, M. J., Berkowitz, N. D. & Higgins, D. E. Directed antigen delivery as a vaccine strategy for an intracellular bacterial pathogen. Proc. Natl Acad. Sci. USA 103 5102-5107 (2006).
64. Happel, K. I. et al. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect. Immun. 73, 5782-5788 (2005).
65. Antoniou, A. N., Blackwood, S. L., Mazzeo, D. & Watts, C. Control of antigen presentation by a single protease cleavage site. Immunity 12, 391-398 (2000).
66. Delamarre, L., Couture, R., Mellman, I. & Trombetta, E. S. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203, 2049-2055 (2006).
67. H1 memory: Implications for vaccine development. Immunol. Rev. 211, 58-66 (2006).
68. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004).
69. Lefrancois, L. & Marzo, A. L. The descent of memory T-cell subsets. Nature Rev. Immunol. 6, 618-623 (2006).
70. Swain, S. L., Hu, H. & Huston, G. Class II-independent generation of CD4 memory T cells from effectors. Science 286, 1381-1383 (1999).
71. Roberts, A. D., Ely, K. H. & Woodland, D. L. Differential contributions of central and effector memory T cells to recall responses. J. Exp. Med. 202, 123-133 (2005).
72. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
73. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
74. Dietrich, J. et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 177 6353-6360 (2006).
75. Mollenkopf, H. J. et al. Application of mycobacterial proteomics to vaccine design: Improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72, 6471-6479 (2004).
76. Goonetilleke, N. P. et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602-1609 (2003).
77. Kaufmann, S. H. E. & McMichael, A. J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature Med. 11, S33-S44 (2005).
78. Marrack, P. & Kappler, J. Control of T cell viability. Annu. Rev. Immunol. 22, 765-787 (2004).
79. + regulatory T cells. J. Immunol. 171, 3348-3352 (2003).
80. + T cells. Immunity 7, 885-895 (1997).
81. Coyle, A. J. et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13, 95-105 (2000).
82. Yoshinaga, S. K. et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402, 827-832 (1999).
83. Mittrucker, H. W. et al. Inducible costimulator protein controls the protective T cell response against Listeria monocytogenes. J. Immunol. 169, 5813-5817 (2002).
84. Hutloff, A. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397, 263-266 (1999).
85. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992).
86. Sharpe, A. H., Wherry, E. J., Ahmed, R. & Freeman, G. J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nature Immunol. 8, 239-245 (2007).
87. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2, 261-268 (2001).
88. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
89. Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257-1266 (2003).
90. MacLeod, M. et al. CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. J. Exp. Med. 203 897-906 (2006).
91. + T lymphocytes. J. Immunol. 152 1523-1531 (1994).
92. McHeyzer-Williams, L. J., Malherbe, L. P. & McHeyzer-Williams, M. G. Helper T cell-regulated B cell immunity. Curr. Top. Microbiol. Immunol. 311, 59-83 (2006).
93. Tarlinton, D. B-cell memory: Are subsets necessary? Nature Rev. Immunol. 6, 785-790 (2006).
94. Zinkernagel, R. M. & Hengartner, H. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol. Rev. 211, 310-319 (2006).
95. Lanzavecchia, A. et al. Understanding and making use of human memory B cells. Immunol. Rev. 211, 303-309 (2006).
96. Cushley, W. & Borland, G. in Immunology (eds Kaufmann, S. H. E. & Steward, M. W.) 303-338 (Hodder Arnold/ASM Press, London/Washington, D.C., 2005).
97. Baumgarth, N., Tung, J. W. & Herzenberg, L. A. Inherent specificities in natural antibodies: A key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26, 347-362 (2005).
98. McHeyzer-Williams, L.J., Cool, M. & McHeyzer-Williams, M. G. Antigen-specific B cell memory: Expression and replenishment of a novel B220-memory B cell compartment. J. Exp. Med. 191, 1149-1166 (2000).
99. Kawabe, T. et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1, 167-178 (1994).
100. Ferguson, S. E., Han, S., Kelsoe, G. & Thompson, C. B. CD28 is required for germinal center formation. J. Immunol. 156, 4576-4581 (1996).
101. Maruyama, M., Lam, K. P. & Rajewsky, K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407, 636-642 (2000).
102. Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133-134 (1997).
103. Slifka, M. K., Antia, R., Whitmire, J. K. & Ahmed, R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363-372 (1998).
104. O'Connor, B. P., Cascalho, M. & Noelle, R. J. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J. Exp. Med. 195, 737-745 (2002).
105. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364-368 (2005).
106. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
107. Pizza, M. et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816-1820 (2000).
108. Kyaw, M. H. et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354, 1455-1463 (2006).
109. Johri, A. K. et al. Group B Streptococcus: Global incidence and vaccine development. Nature Rev. Microbiol. 4, 932-942 (2006).
110. Projan, S. J., Nesin, M. & Dunman, P. M. Staphylococcal vaccines and immunotherapy: To dream the impossible dream? Curr. Opin. Pharmacol. 6, 473-479 (2006).
111. Gotz, F. Staphylococci in colonization and disease: Prospective targets for drugs and vaccines. Curr. Opin. Microbiol. 7, 477-487 (2004).
112. McMillan, D. J. & Chhatwal, G. S. Prospects for a group A streptococcal vaccine. Curr. Opin. Mol. Ther. 7, 11-16 (2005).
113. Olive, C. Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease. Curr. Opin. Mol. Ther. 9, 25-34 (2007).
114. Kotloff, K.L. et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: Phase 1 trial. JAMA 292, 709-715 (2004).
115. Maione, D. et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309 148-150 (2005).
116. Mora, M., Donati, C., Medini, D., Covacci, A. & Rappuoli, R. Microbial genomes and vaccine design: Refinements to the classical reverse vaccinology approach. Curr. Opin. Microbiol. 9, 532-536 (2006).
117. Wizemann, T. M. et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69, 1593-1598 (2001).
118. De Groot, A. S. Immunomics: Discovering new targets for vaccines and therapeutics. Drug Discov. Today 11, 203-209 (2006).
119. Giefing, C., Nagy, E. & von Gabain, A. in Pharmaceutical Biotechnology (eds Guzman, C. A. & Feuerstein, G.) in press (Landes Bioscience, Austin, Texas).
120. Etz, H. et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 99, 6573-6578 (2002).
121. Kuklin, N. A. et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74, 2215-2223 (2006).
122. Kaufmann, S. H. E. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26, 660-667 (2005).
123. Kaufmann, S. H. E. Envisioning future strategies for vaccination against tuberculosis. Nature Rev. Immunol. 6, 699-704 (2006).
124. Young, D. & Dye, C. The development and impact of tuberculosis vaccines. Cell 124, 683-687 (2006).
125. Andersen, P. & Doherty, T. M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nature Rev. Microbiol. 3, 656-662 (2005).
126. Brockstedt, D. G. et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature Med. 11, 853-860 (2005).
127. Kursar, M. et al. Cutting edge: Regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 178, 2661-2665 (2007).
128. Brunham, R. C. & Rey-Ladino, J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nature Rev. Immunol. 5, 149-161 (2005).
129. Aebischer, T., Schmitt, A., Walduck, A. K. & Meyer, T. F. Helicobacter pylori vaccine development: Facing the challenge. Int. J. Med. Microbiol. 295, 343-353 (2005).
130. Suerbaum, S. & Michetti, P. Helicobacter pylori infection. N. Engl. J. Med. 347, 1175-1186 (2002).
131. Baker, M. Anti-infective antibodies: Finding the path forward. Nature Biotechnol. 24, 1491-1493 (2006).
132. Vitetta, E. S. & Ghetie, V. F. Considering therapeutic antibodies. Science 313, 308-309 (2006).
133. Kim, C. & Kaufmann, S. H. Defensin: A multifunctional molecule lives up to its versatile name. Trends Microbiol. 14, 428-431 (2006).
134. Kim, C. et al. Human α-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc. Natl Acad. Sci. USA 102, 4830-4835 (2005).
135. Killian, M. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 833-881 (Hodder Arnold, London, 2005).
136. Sinha, A., Levine, O., Knoll, M. D., Muhib, F. & Lieu, T. A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: An international economic analysis. Lancet 369, 389-396 (2007).
137. Mietzner, T. A. & Morse, S. A. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 1270-1300 (Hodder Arnold, London, 2005).
138. Smith, A. et al. Invasive group A streptococcal disease: Should close contacts routinely receive antibiotic prophylaxis? Lancet Infect. Dis. 5, 494-500 (2005).
139. Bisno, A. L., Brito, M. O. & Collins, C. M. Molecular basis of group A streptococcal virulence. Lancet Infect. Dis. 3, 191-200 (2003).
140. Areschoug, T., Carlsson, F., Stalhammar-Carlemalm, M. & Lindahl, G. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development. Vaccine 22 (Suppl 1), S9-S14 (2004).
141. Pfffer, G. E. & Vincent, V. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 1181-1235 (Hodder Arnold, London, 2005).
142. Märdh, P.-A. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 2006-2025 (Hodder Arnold, London, 2005).
143. Owen, R. J. in Bacteriology Vol. 2. (eds Borriello, S. P., Murray, P. R. & Funke, G.) 1563-1590 (Hodder Arnold, London, 2005).